Diamyd® Diabetes Vaccine - Three Blockbuster Indications
Diamyd Medical reports that the Diamyd® vaccine may be effective in preventing
type 1 diabetes in individuals that have not yet presented clinical symptoms.
As reported in New England Journal of Medicine (Oct 30, 2008), Diamyd® preserves
insulin producing beta cells best in patients recently diagnosed with the
disease. Beta cell destruction is a consecutive process, eventually leading to
the need for life-long treatment with insulin. Diamyd® given before clinical
presentation could hence prevent the onset of the disease. "This is good news for individuals at risk for type 1 diabetes”, says Elisabeth
Lindner, President and CEO of Diamyd Medical. Several large programs are in full
operation around the world with the goal to screen thousands of small children
for their risk to develop type 1 diabetes. These children could all benefit from
vaccination with Diamyd®.
Beyond the vaccine application for type 1 diabetes, Diamyd® has shown effect in
preventing insulin treatment in a study including GAD antibody positive patients
with type 2 diabetes, representing 10% of all type 2 diabetes patients. The data
were recently presented by Professor Carl-David Agardh, Lund University, Sweden.
The three applications; treatment and prevention of type 1 diabetes, as well as
prevention of insulin treatment in autoimmune type 2 diabetes, are all believed
to have blockbuster potential.
For further information, please contact:
Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.),
Elisabeth.Lindner@diamyd.com
Phone: +46-8-661 0026
For pictures and press material, please contact:
Sonja Catani, Chief Communications Officer Diamyd Medical AB (publ.),
Sonja.Catani@diamyd.com
Phone: +46-8-661 0026
Diamyd Medical AB (publ.)
Linnégatan 89 B, SE-115 23 Stockholm, Sverige. Tel: +46 8 661 00 26, Fax: +46 8
661 63 68 E-post: info@diamyd.com. VATno: SE556530-142001.
About Diamyd Medical:
Diamyd Medical is a Swedish biopharmaceutical company focusing on development of
pharmaceuticals for treatment of autoimmune diabetes and its complications. The
company's most advanced project is the GAD-based drug Diamyd® for type 1
diabetes and for which Phase III trials are ongoing in both the US and Europe.
Furthermore, the company has initiated clinical studies within chronic pain,
using its Nerve Targeting Drug Delivery System (NTDDS). The company has also
out-licensed the use of GAD for the treatment of Parkinson's disease.
Diamyd Medical has offices in Sweden and in the US. The share is quoted on the
OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker:
DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further
information is available on the company's web site: www.diamyd.com.
This information is disclosed in accordance with the Securities Markets Act, the
Financial Instruments Trading Act or demands made in the exchange rules.
